194 related articles for article (PubMed ID: 1971771)
21. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
[TBL] [Abstract][Full Text] [Related]
22. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.
Szepesházi K; Halmos G; Schally AV; Arencibia JM; Groot K; Vadillo-Buenfil M; Rodriguez-Martin E
J Cancer Res Clin Oncol; 1999; 125(8-9):444-52. PubMed ID: 10480336
[TBL] [Abstract][Full Text] [Related]
23. Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin.
Szende B; Lapis K; Redding TW; Srkalovic G; Schally AV
Breast Cancer Res Treat; 1989 Dec; 14(3):307-14. PubMed ID: 2575407
[TBL] [Abstract][Full Text] [Related]
24. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
Szepeshazi K; Schally AV; Groot K; Halmos G
Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
[TBL] [Abstract][Full Text] [Related]
25. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
Torres-Aleman I; Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1252-6. PubMed ID: 2858096
[TBL] [Abstract][Full Text] [Related]
27. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Pinski J; Halmos G; Szepeshazi K; Schally AV
Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
[TBL] [Abstract][Full Text] [Related]
28. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
Kadar T; Redding TW; Ben-David M; Schally AV
Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
[TBL] [Abstract][Full Text] [Related]
29. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors.
Lee MT; Liebow C; Kamer AR; Schally AV
Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1656-60. PubMed ID: 1672042
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin.
de Quijada MG; Redding TW; Coy DH; Torres-Aleman I; Schally AV
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3485-8. PubMed ID: 6134284
[TBL] [Abstract][Full Text] [Related]
31. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
Redding TW; Schally AV
Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
[TBL] [Abstract][Full Text] [Related]
32. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.
Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
J Natl Cancer Inst; 1990 Mar; 82(6):513-7. PubMed ID: 2156080
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV
Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
Halmos G; Schally AV; Kahan Z
Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally AV
Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7090-4. PubMed ID: 7518926
[TBL] [Abstract][Full Text] [Related]
36. Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.
Schally AV; Redding TW
Proc Natl Acad Sci U S A; 1985 Apr; 82(8):2498-502. PubMed ID: 3157990
[TBL] [Abstract][Full Text] [Related]
37. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia.
Fekete M; Redding TW; Comaru-Schally AM; Pontes JE; Connelly RW; Srkalovic G; Schally AV
Prostate; 1989; 14(3):191-208. PubMed ID: 2471961
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
Yano T; Korkut E; Pinski J; Szepeshazi K; Milovanovic S; Groot K; Clarke R; Comaru-Schally AM; Schally AV
Breast Cancer Res Treat; 1992; 21(1):35-45. PubMed ID: 1391973
[TBL] [Abstract][Full Text] [Related]
40. Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation.
Liebow C; Lee MT; Kamer AR; Schally AV
Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2244-8. PubMed ID: 1672452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
